SentiAR has closed a Series B financing round worth US$8.5 million. The financing was led by cultivate (MD) Ventures and joined by MedVenture Partners alongside several insider investors, including TechWald Holding, VCapital, QRM Capital, and Harmonix Fund. The funding will allow the company to launch additional partnerships and wider clinical deployments.
The company’s innovative first product, CommandEP, integrates existing imaging systems to create a real time 3D holographic interface. This interface provides physicians with an interactive, 360-degree view of the patient’s specific anatomy to allow them to deliver cardiac ablation therapy to patients.
The CommandEP system utilises a specially designed headset worn by the physician allowing hands-free manipulation of the patient’s data for the first time, in addition to real-time heart anatomy and catheter locations inside the heart. The CommandEP system is designed to be utilised during cardiac ablation procedures to increase physician navigation accuracy and speed.
Berk Tas, CEO of SentiAR, said: “We are delighted to welcome new investors. This funding allows us to meet the great interest from physicians for this first of its kind application. We look forward to working with our clinical and strategic partners as we scale up clinical deployments.”
Jag Singh (Harvard Medical School, Boston, USA), said: “We have been looking for a tool like this for a long time. The CommandEP system’s ability to provide full 3D visualisation in real-time and giving us the ability to control our images, hands-free, for the first time is exciting. We look forward to the potential benefits of CommandEP for our patients.”
SentiAR anticipates completion of new clinical studies of the CommandEP system in the second half of this year.